Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBR-900
- Development stage
- Phase 1
- Lead developer
- Glenmark Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
GBR-900 is a first-in-class humanized monoclonal antibody that acts as an antagonist of the tropomyosin receptor kinase A (TrkA), which is the high-affinity receptor for nerve growth factor (NGF). By targeting TrkA, GBR-900 aims to block NGF-mediated pain signaling pathways involved in chronic pain conditions. The drug was originally developed by Lay Line Genomics and later licensed to Glenmark Pharmaceuticals for further development. Preclinical studies indicated that GBR-900 may have a favorable safety profile compared to anti-NGF antibodies and demonstrated efficacy in animal models of inflammatory pain. Its primary indication has been chronic pain; however, clinical development appears to have stalled after completion of phase 1 trials in healthy volunteers[1][2][4][5].
- Other names
- HMNAC-13HMNAC13HMNAC 13
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on GBR-900.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBR-900.